Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eflornithine oral - Orbus Therapeutics

Next Previous
Drug Profile

Eflornithine oral - Orbus Therapeutics

Latest Information Update: 29 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orbus Therapeutics
  • Class Antihyperglycaemics; Antineoplastics; Basic amino acids; Diamino amino acids; Small molecules
  • Mechanism of Action Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaplastic astrocytoma
  • Phase I Glioblastoma

Most Recent Events

  • 25 Nov 2024 Interim efficacy and adverse events data from a phase III STELLAR trial in Astrocytoma released by Orbus Therapeutics
  • 26 May 2023 Phase-I clinical trials in Glioblastoma (First line therapy, Combination therapy) in USA (PO) (NCT05879367)
  • 10 Jan 2023 Orbus Therapeutics in-licenses intellectual property covering methods of use of eflornithine in Bachmann-Bubb syndrome from Michigan State University and Helen DeVos Children’s Hospital

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top